---
title: Insights | Peter Kienholz
description: Peter Kienholz joined Siegfried in 2019 and currently serves as Head Corporate Development. In this role, he leads the company’s Commercial Excellence functions and drives strategic initiatives across the organization. Previously, he also oversaw Siegfried's global Supply Chain. Before joining the company, Peter served as a Principal at the Boston Consulting Group, where he was a core member of the firm’s Industrial Goods and Operations practices and advised clients primarily across Europe and the Asia-Pacific region. Peter holds a Master of Science degree in Theoretical Physics.
---

This is a search field with an auto-suggest feature attached.

- There are no suggestions because the search field is empty.

- [Careers](https://www.siegfried.ch/careers/)
- [Media](https://www.siegfried.ch/media/)
- [Investors](https://www.siegfried.ch/investors/)
- [Contact us](https://www.siegfried.ch/contact/)

[Company](https://www.siegfried.ch/company/)

Company

[Purpose](https://www.siegfried.ch/company/purpose/)

[Strategy](https://www.siegfried.ch/company/strategy/)

[Leadership](https://www.siegfried.ch/company/leadership/)

[History](https://www.siegfried.ch/company/history/)

[Locations](https://www.siegfried.ch/company/locations/)

[Offering](https://www.siegfried.ch/offering/)

Offering

[Drug Substances](https://www.siegfried.ch/offering/drug-substances/)

[Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub) [Alkaloid raw materials extraction](https://extractas.com.au/)

[Drug Products](https://www.siegfried.ch/offering/drug-products/)

[Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/)

[Technologies](https://www.siegfried.ch/technologies/)

[Sustainability](https://www.siegfried.ch/sustainability/)

Sustainability

[People](https://www.siegfried.ch/sustainability/people/)

[Environment](https://www.siegfried.ch/sustainability/environment/environment/)

[Integrity](https://www.siegfried.ch/sustainability/integrity/)

[Quality](https://www.siegfried.ch/sustainability/quality/)

[Community engagement](https://siegfried.ch/sustainability/community-engagement/)

[Risk management](https://www.siegfried.ch/sustainability/risk-management/)

[Insights](https://content.siegfried.ch/insights)

[![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/)

What are you  
looking for?

[![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/)

[Company](https://www.siegfried.ch/company/)

[Purpose](https://www.siegfried.ch/company/purpose/)

[Strategy](https://www.siegfried.ch/company/strategy/)

[Leadership](https://www.siegfried.ch/company/leadership/)

[History](https://www.siegfried.ch/company/history/)

[Locations](https://www.siegfried.ch/company/locations/)

[Offering](https://www.siegfried.ch/offering/)

[Drug Substances](https://www.siegfried.ch/offering/drug-substances/)

[Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub) [Alkaloid raw materials extraction](https://extractas.com.au/)

[Drug Products](https://www.siegfried.ch/offering/drug-products/)

[Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/)

[Technologies](https://www.siegfried.ch/technologies/)

[Sustainability](https://www.siegfried.ch/sustainability/)

[People](https://www.siegfried.ch/sustainability/people/)

[Environment](https://www.siegfried.ch/sustainability/environment/environment/)

[Integrity](https://www.siegfried.ch/sustainability/integrity/)

[Quality](https://www.siegfried.ch/sustainability/quality/)

[Community engagement](https://siegfried.ch/sustainability/community-engagement/)

[Risk management](https://www.siegfried.ch/sustainability/risk-management/)

[Insights](https://content.siegfried.ch/insights)

- [Careers](https://www.siegfried.ch/careers/)
- [Media](https://www.siegfried.ch/media/)
- [Investors](https://www.siegfried.ch/investors/)
- [Contact us](https://www.siegfried.ch/contact/)

# Insights

## See our event recap

<iframe data-hsv-src="https://play-eu1.hubspotvideo.com/v/143616667/id/292584136913?play_button_color=ffffff" referrerpolicy="origin" sandbox="allow-forms allow-scripts allow-same-origin allow-popups" allow="autoplay; fullscreen;" style="position: absolute !important; width: 100% !important; height: 100% !important; left: 0; top: 0; border: 0 none; pointer-events: initial" title="HubSpot Video" loading="lazy" data-hsv-id="292584136913" data-hsv-play-button-color="ffffff" data-hsv-width="1920" data-hsv-height="1080" data-hsv-full-width="false"></iframe>

Filter by tags

[Technology](https://content.siegfried.ch/insights/tag/technology) [Early-phase development](https://content.siegfried.ch/insights/tag/early-phase-development) [Sustainability](https://content.siegfried.ch/insights/tag/sustainability) [Drug Products](https://content.siegfried.ch/insights/tag/drug-products) [Regulatory support](https://content.siegfried.ch/insights/tag/regulatory-support)

[Technology](https://content.siegfried.ch/insights/tag/technology) [Early-phase development](https://content.siegfried.ch/insights/tag/early-phase-development) [Sustainability](https://content.siegfried.ch/insights/tag/sustainability) [Drug Products](https://content.siegfried.ch/insights/tag/drug-products) [Regulatory support](https://content.siegfried.ch/insights/tag/regulatory-support) [Oral solid dosage form](https://content.siegfried.ch/insights/tag/oral-solid-dosage-form) [Scale-up](https://content.siegfried.ch/insights/tag/scale-up) [Dosage Form](https://content.siegfried.ch/insights/tag/dosage-form) [Fill-finish](https://content.siegfried.ch/insights/tag/fill-finish) [Pharmaceutical Manufacturing](https://content.siegfried.ch/insights/tag/pharmaceutical-manufacturing) [Pre-filled syringes](https://content.siegfried.ch/insights/tag/pre-filled-syringes)

NEW

 05/12/2025

### Small molecules, growing complexities: Navigating shifts in supply chain and manufacturing

[Read article](https://content.siegfried.ch/insights/smallmoleculesbigchanges)

Recent

#### [Sep 28, 2026 Drug Products Oral solid dosage form Accelerating early-stage CMC development for oral drug products](https://content.siegfried.ch/insights/accelerating-early-stage-cmc-development-for-oral-drug-products-1)

#### [Aug 19, 2026 Early-phase development Regulatory support More than compliance: Managing the challenges of controlled substance manufacturing](https://content.siegfried.ch/insights/more-than-compliance-managing-the-challenges-of-controlled-substance-manufacturing)

#### [Jul 23, 2026 Scale-up Drug Products Dosage form scale-up: Balancing speed and efficiency in later-stage development](https://content.siegfried.ch/insights/dosage-form-scale-up-balancing-speed-and-efficiency-in-later-stage-development)

#### Subscribe for more expert insights

 

All posts

### [May 12, 2025 Small molecules, growing complexities: Navigating shifts in supply chain and manufacturing](https://content.siegfried.ch/insights/smallmoleculesbigchanges)

Oct 30, 2025

### Video: Insights from Chief Scientific Officer Stefan Randl at CPHI Frankfurt 2025

Sign up to stay up to date on Siegfried and our business performance.

 expect more

**Siegfried AG**

Untere Brühlstrasse 4  
4800 Zofingen, Switzerland

[+41 62 746 11 11](tel:+41627461111) [Get in touch](https://www.siegfried.ch/contact-us/)

#### About us

- [Our company](https://www.siegfried.ch/company/)
- [Sustainability](https://www.siegfried.ch/sustainability/)
- [Media](https://www.siegfried.ch/media/)
- [Investors](https://www.siegfried.ch/investors/)
- [Careers](https://www.siegfried.ch/careers/)

#### Helpful resources

- [Expert insights](https://content.siegfried.ch/insights)
- [News archive](https://www.siegfried.ch/news-archive/)
- [Reports](https://www.siegfried.ch/investors/investors-download-center-2025/)
- [Terms and conditions](https://www.siegfried.ch/terms-and-conditions/)

#### Offering

- [Drug Substances](https://www.siegfried.ch/offering/drug-substances/)
- [Drug Products](https://www.siegfried.ch/offering/drug-products/)
- [Technologies](https://www.siegfried.ch/technologies/)

2026 © Siegfried Holding AG

<https://www.linkedin.com/company/50322/admin/feed/posts/>

- [Privacy Policy](https://www.siegfried.ch/privacy-policy/)
- [Legal disclaimer](https://www.siegfried.ch/legal-disclaimer/)
- [Imprint](https://www.siegfried.ch/imprint/)

```json
{
  "@context" : "https://schema.org",
  "@type" : "VideoObject",
  "contentUrl" : "https://143616667.fs1.hubspotusercontent-eu1.net/hubfs/143616667/Peter%20-%20Video%2001%20Final%20v2.mp4",
  "dateModified" : "2025-10-31T17:20:09.538Z",
  "duration" : "PT2M16S",
  "height" : 1080,
  "name" : "Peter - Video 01 Final v2",
  "thumbnailUrl" : "https://143616667.fs1.hubspotusercontent-eu1.net/hubfs/143616667/Peter%20-%20Video%2001%20Final%20v2.mp4/medium.jpg",
  "uploadDate" : "2025-10-28T21:59:19.239Z",
  "width" : 1920
}
```